Handelsbanken Fonder AB Has $281,000 Stake in Astrana Health, Inc. (NASDAQ:ASTH)

Handelsbanken Fonder AB increased its holdings in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 4.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 8,900 shares of the company’s stock after purchasing an additional 400 shares during the period. Handelsbanken Fonder AB’s holdings in Astrana Health were worth $281,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC acquired a new position in Astrana Health in the 3rd quarter valued at $35,000. KBC Group NV acquired a new stake in shares of Astrana Health during the 3rd quarter valued at $70,000. Quarry LP bought a new position in Astrana Health in the 3rd quarter valued at approximately $77,000. Quest Partners LLC bought a new stake in shares of Astrana Health in the third quarter worth $133,000. Finally, Paloma Partners Management Co acquired a new stake in Astrana Health in the third quarter valued at $220,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Stock Up 4.3 %

Astrana Health stock opened at $26.48 on Tuesday. Astrana Health, Inc. has a 1-year low of $23.12 and a 1-year high of $63.20. The firm has a 50 day simple moving average of $34.84 and a 200 day simple moving average of $44.46. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of 20.37, a P/E/G ratio of 1.37 and a beta of 1.20.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $665.21 million for the quarter, compared to the consensus estimate of $617.24 million. On average, analysts predict that Astrana Health, Inc. will post 1.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ASTH shares. Truist Financial reduced their price objective on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, January 13th. Macquarie raised Astrana Health to a “hold” rating in a report on Monday, December 16th. Stifel Nicolaus cut their price objective on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, February 20th. Finally, Robert W. Baird cut their price objective on Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research report on Monday. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $58.40.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.